AIMTC Inc Ordinary Shares TCAI 深 滬
等待開盤 09-22 09:30:00 美东时间
28.75
+0.340
+1.20%
華盛通- 最 高28.75
- 今 開28.66
- 成交量 3.41万股
- 最 低 28.33
- 昨 收 28.41
- 總市值 575.00万
- 52周最高 29.17
- 市盈率 靜 --
- 換手率 17.04%
- 52周最低 24.45
- 委 比 0.00%
- 總股本 20.00万
- 歷史最高 29.17
- 量 比 2.01
- 振 幅 1.48%
- 歷史最低 24.45
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
AIM ImmunoTech Inc. announced the presentation of positive progress from its Ampligen clinical program for pancreatic cancer at the 5th Annual Marie Skłodowska-Curie Symposium. CEO Thomas K. Equels highlighted data from Ampligen's Early Access Program and the Phase 2 DURIPANC trial, showing promising Progression-Free Survival and Overall Survival. Ampligen is being tested with AstraZeneca's durvalumab and has orphan drug designations and patent p...
09-04 15:00
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Inc. CEO Thomas Equels provided a corporate update in the latest CEO Corner, highlighting progress with lead product candidate Ampligen in pancreatic cancer. Ampligen, a first-in-class dsRNA and TLR3 agonist, is in clinical trials for cancers, viral diseases, and immune disorders. For more information, visit aimimmuno.com. This press release contains forward-looking statements subject to risks and uncertainties; refer to the compan...
08-21 13:00
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
<p>AIM ImmunoTech reported positive progress in its pancreatic cancer pipeline programs, highlighting promising Phase 2 trial results for Ampligen® in combination with Imfinzi®. The company also bolstered its cash position with an $8 million equity offering, funding operations for approximately 12 months. Key updates included resumed trading on NYSE American, a mid-year clinical data update, and upcoming scientific presentations. Financial highli...
08-15 13:00
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
<p>Live video webcast on Wednesday, August 20th at 2:40 PM ET</p> <p>OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), today announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, held virtually August 19-21, 2025. The presentation will be on Wednesday, August 20, 2025 at 2:40 PM ET, presented by Thomas Equels, CEO, President & Executive Vice Chairman. Registra...
08-14 12:55
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
AIM ImmunoTech Inc. announced that its drug Ampligen will present updates on its progress in late-stage pancreatic cancer, multiple solid tumor types, and its mechanism of action in oncology at the 5th Annual Marie Sklodowska-Curie Symposium in Warsaw, Poland, September 3-5, 2025. The presentations will include recent data from the DURIPANC study, showing promising survival outcomes and safety profiles, as well as Ampligen’s potential as a thera...
08-06 13:00
New ETF Digs Into Pipes, Power And Plugs Behind The AI Revolution
The Tortoise AI Infrastructure ETF is a unique way to invest in the infrastructure that powers the AI revolution. It focuses on energy, data centers, and technology infrastructure. Tortoise's expertise in this sector and its risk-disciplined approach make this ETF stand out. Launch date: August 4. Price at listing: ~$25.27. Expense ratio: 0.65%.
08-06 03:08
